论文部分内容阅读
目的：观察头孢哌酮-舒巴坦治疗下呼吸道感染的临床疗效及细菌对该药的耐药性。方法：下呼吸道感染住院病人７３例［男性５３例，女性２０例，年龄（５７ ± ｓ １４） ａ］，应用头孢派酮一舒巴坦 ２． ０ ｇ，加入 ０． ９％氯化钠注射液 １００ ｍｌ。中静脉滴注， ｂｉｄ，疗程（１０ ± ３） ｄ；并对我院临床分离的 ７３８株致病菌进行药敏试验。结果：应用头孢哌酮－舒巴坦治疗的有效率为 ９２％，细菌清除率为 ８４％。头孢哌酮－舒巴坦对临床分离的革兰阴性杆菌的敏感性为 ９４％，对革兰阳性球菌的敏感性为 ８６％。结论：头孢哌酮－舒巴坦治疗下呼吸道感染的临床疗效好，细菌耐药性低，是一种抗菌谱广、杀菌作用强的耐酶抗生素。
Objective: To observe the clinical efficacy of cefoperazone-sulbactam in the treatment of lower respiratory tract infections and the drug resistance of the bacteria to the drug. Methods: Inpatients with lower respiratory tract infection were 73 (53 males, 20 females, 57 ± 14 days) with cefoperazone-sulbactam 2. 0 g, add 0. 9% sodium chloride injection 100 ml. Middle intravenous drip, bid, treatment (10 ± 3) d; and clinical isolates of 738 pathogenic bacteria susceptibility testing. Results: The effective rate of treatment with cefoperazone-sulbactam was 92% and the bacterial clearance rate was 84%. Cefoperazone-sulbactam was 94% sensitive to clinically gram-negative bacilli and 86% sensitive to gram-positive cocci. CONCLUSION: Cefoperazone-sulbactam is effective in treating lower respiratory tract infection and has low bacterial resistance. It is a kind of antibiotic-resistant antibiotic with broad antibacterial spectrum and bactericidal effect.